The Board of Directors in Elekta sets the terms for the rights issue of convertible bonds with preferential rights for the company’s shareholders

The Board of Directors in Elekta sets the terms for the rights issue of
convertible bonds with preferential rights for the company’s shareholders

NOT FOR PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN, HONG
KONG OR AUSTRALIA

Press release
Stockholm, Sweden, March 30, 2012

  · Shareholders in Elekta have preferential rights to subscribe for one new
convertible bond of series A and series B, for every existing share of series A
and Series B, respectively
  · The subscription price will be SEK 20 per convertible bond, which represents
total rights issue proceeds of approximately SEK 1,894 M
  · The coupon rate has been set to 2.75 percent per annum and the conversion
price has been set to SEK 390
  · The subscription period runs from and including April 11 up to and including
April 25, 2012 and the record date will be on April 5, 2012

The Board of Directors in Elekta has resolved to set the terms for the rights
issue of convertible bonds that was decided on March 2, 2012. The rights issue
is subject to approval by the Extraordinary General Meeting which will be held
on April 2, 2012.

For every share of Series A held in Elekta, the holder is entitled to one Series
A subscription right, and for every share of Series B held in Elekta, the holder
is entitled to one Series B subscription right. One Series A subscription right
entitles the holder to subscribe for one Series A convertible bond at the
subscription price of SEK 20 and one Series B subscription right entitles the
holder to subscribe for one Series B convertible bond at the subscription price
of SEK 20, corresponding to the nominal value of the convertible bond. The
subscription price of SEK 20 implies that the rights issue will raise a maximum
of SEK 1,894,493,500 before transaction costs.

The convertible bonds carry an annual interest rate of 2.75 percent. Interest
shall be paid annually in arrears on August 31, save that the first payment of
interest will be made on August 31, 2012 in respect of the period from (and
including) April 25, 2012 to (but excluding) August 31, 2012, and the last
payment of interest will be made on April 25, 2017 in respect of the period from
(and including) August 31, 2016 to (but excluding) April 25, 2017. The
convertible bond matures for payment for the nominal amount on April 25, 2017,
unless conversion or repayment has occurred prior to such date.

The conversion price has been set to SEK 390 and bondholders have the right to
require conversion of some convertible bonds into new shares in Elekta at any
time during the period commencing on the date of registration of the terms and
conditions for the convertible bonds with the Swedish Companies Registration
Office and ending on March 28, 2017. At full conversion, the number of shares of
Series A will increase by 182,692 and the number of shares of Series B will
increase by 4,674,983 corresponding to a total dilution of the company’s share
capital of approximately 4.9 percent. The complete terms and conditions for the
convertible bonds are available at www.elekta.com.

The rights issue aims to increase Elekta’s financial and strategic flexibility
to act on the growth opportunities the company sees going forward as well as to
increase diversification of Elekta’s financing instruments and lower the
reliance on bank debt.

The record date at the Swedish Central Securities Depository, Euroclear Sweden
AB, for participation in the rights issue is April 5, 2012. The subscription
period will run from and including April 11 up to and including April 25, 2012,
or such later date as decided by the Board of Directors.

An information brochure or prospectus as well as a pre-printed issue statement
will be sent to directly registered shareholders in Elekta on or around April
11, 2012.

Timetable for the rights issue

April 2,   Extraordinary General Meeting decides on the rights issue resolved
2012       by the Board of Directors
April 3,   First day of trading in the shares, excluding right to participate
2012       in the rights issue
April 5,   Record date for participation in the rights issue, i.e.
2012       shareholders registered in the share register of Elekta as of this
           day will receive subscription rights for participation in the
           rights issue
           Estimated date of publication of the prospectus
April 11   Trading in subscription rights
-20, 2012
April 11   Subscription period
-25, 2012
Around     Announcement of preliminary outcome of the rights issue
May 2,
2012

Elekta intends to list the subscription rights relating to Series B convertible
bonds and the Series B convertible bonds on NASDAQ OMX Stockholm.

Extraordinary General Meeting

The Board of Directors’ resolution of a rights issue is subject to approval by
an Extraordinary General Meeting to be held at 10:00 CET on Monday April 2, 2012
at the Company’s premises at Kungstensgatan 18 in Stockholm. The notice of the
Extraordinary General Meeting was published on March 7, 2012 and is available at
www.elekta.com.

Financial and legal advisors

SEB Enskilda is acting as financial advisor to Elekta and Deutsche Bank AG and
SEB Enskilda are acting as Joint Bookrunners. Hannes Snellman is acting as legal
advisor to Elekta.

For further information, please contact:
Håkan Bergström, CFO, Elekta AB (publ)
Tel: +46 8 587 25 547, email: hakan.bergstrom@elekta.com

Johan Andersson Melbi, Investor Relations Manager, Elekta AB (publ)
Tel: +46 702 100 451, email: johan.anderssonmelbi@elekta.com

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on March 30, 2012.

******

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,300 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb.

IMPORTANT NOTICE
These materials are not an offer of securities for sale in the United States.
Securities may not be offered or sold in the United States absent registration
or an exemption from registration under the United States Securities Act of
1933, as amended (the “Securities Act”). The securities to which these materials
relate have not been and will not be registered under the Securities Act and
there will be no public offering of the securities in the United States.

No offer or invitation to acquire securities of Elekta AB (publ) is being made
by or in connection with this release. Any such offer will be made solely by
means of the prospectus that Elekta AB (publ) will prepare: (i) once it has been
approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen)
in accordance with the Swedish Financial Instruments Trading Act and the
Directive 2003/71/EC; and (ii) published in accordance with Swedish law,
together with its English translation, (each as supplemented or amended), to, in
each case, the persons entitled to receive and rely upon such documents in
accordance with their respective terms.

This communication is directed in the United Kingdom solely to persons who: (i)
have professional experience in matters relating to investments and who fall
within the meaning of Article 19(5) of the Financial Services and Markets Act
2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) are high net worth
entities falling within Article 49(2)(a) to (d) of the Order and other persons
to whom such communication may otherwise lawfully be made (all such persons
together being referred to as the “Relevant Persons”). This communication must
not be acted on or relied on by persons who are not the Relevant Persons. Any
investment or investment activity to which this communication relates is
available only to the Relevant Persons and will be engaged in only with the
Relevant Persons. Persons distributing this communication must satisfy
themselves that it is lawful to do so.

Deutsche Bank AG is authorised under German Banking Law (competent authority:
BaFin – Federal Financial Supervisory Authority) and authorised and subject to
limited regulation by the Financial Services Authority. Details about the extent
of Deutsche Bank AG’s authorisation and regulation by the Financial Services
Authority are available on request.